carbidopa has been researched along with Nerve Degeneration in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (33.33) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fonseca-Ornelas, L; Hernández-Vargas, R; López-González, I; Reynaud, E; Riesgo-Escovar, J; Zurita, M | 1 |
Fukui, M; Kang, KS; Wen, Y; Yamabe, N; Zhu, BT | 1 |
Delville, Y; Fleming, SM; Schallert, T | 1 |
Finn, BW; Mendez, JS | 1 |
Marsden, CD; Pires, M; Quinn, NP; Scaravilli, F; Steiger, MJ | 1 |
Gibb, WR; Kempster, PA; Lees, AJ; Stern, GM | 1 |
6 other study(ies) available for carbidopa and Nerve Degeneration
Article | Year |
---|---|
Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Blotting, Western; Carbidopa; Carrier Proteins; Disease Models, Animal; Drosophila; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Motor Activity; Nerve Degeneration; Nerve Tissue Proteins; Neurotoxicity Syndromes; Parkinson Disease; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antiparkinson Agents; Carbidopa; Catechin; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Disease Models, Animal; Excitatory Amino Acid Agonists; Fluoresceins; Glial Fibrillary Acidic Protein; Hippocampus; Hydroxybenzoates; In Vitro Techniques; Kainic Acid; Levodopa; Male; Methylation; Mice; Nerve Degeneration; Neurons; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors; Tyrosine | 2013 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats.
Topics: Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Hydroxydopamines; Levodopa; Male; Movement; Nerve Degeneration; Neurons; Neurotransmitter Agents; Oxotremorine; Parkinson Disease, Secondary; Rats; Rotation; Stereotaxic Techniques; Substantia Nigra; Synaptic Transmission; Time Factors | 1975 |
Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration.
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Carbidopa; Central Nervous System Diseases; Chorea; Diagnosis, Differential; Drug Combinations; Female; Humans; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Spinal Cord | 1992 |
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
Topics: Adult; Aged; Carbidopa; Disability Evaluation; Dominance, Cerebral; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Nerve Degeneration; Parkinson Disease; Substantia Nigra | 1989 |